Tag Archives: Disease-Modifying Treatments for Dementia

The State of Dementia Research Globally: World Alzheimer Report 2018 (Alzheimer’s Disease International)

Posted on March 2, 2019 by Dementia and Elderly Care News

Summary The World Alzheimer Report 2018, entitled “The state of the art of dementia research: New frontiers”, reviews developments in dementia research, without glossing-over the absence of significant disease-modifying pharmacological treatment breakthroughs for around 20 years. This report examines wide-ranging … Continue reading →

Posted in Acute Hospitals, Alzheimer’s Disease International (ADI), Charitable Bodies, Community Care, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Person-Centred Care, Quick Insights, Standards, Statistics, UK, Universal Interest | Tagged ADI’s World Alzheimer Reports, Alireza Atri: Director of Banner Sun Health Research Institute, Alzheimer's Research, Alzheimer’s Disease International (ADI), Alzheimer’s Disease Research Unit: McGill Centre for Studies in Ageing (Canada), Alzheimer’s Prevention Initiative: Banner Health (USA), Alzheimer’s Prevention Initiative: Banner Sun Health Research Institute, Banner Sun Health Research Institute, Burden of Alzheimer’s Disease, Burden of Dementia (Statistics), Centre for Dementia Prevention: University of Edinburgh, Dementia as Cause of Death, Dementia Awareness, Dementia Awareness Raising, Dementia Collaborative Research Centre: University of New South Wales, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Prevention, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Disease-Modifying Treatments for Dementia, Dr Christopher Chen: Director of Memory Ageing and Cognition Centre at National University Health System: Singapore, Dr Doug Brown: Chief Executive Officer of British Society for Immunology, Dr Doug Brown: Former Chief Policy and Research Officer at Alzheimer’s Society, Dr Jennifer Bute: Dementia Alliance International (DAI), Dr Kenji Toba: President of National Centre for Geriatrics and Gerontology (Obu), Dr Maria Carrillo: Chief Science Officer at Alzheimer’s Association US, Dr Miia Kivipelto: Karolinska Institute, Dr Miia Kivipelto: Karolinska University Hospital (Stockholm), Dr Rachelle Doody: Global Head of Neurodegeneration at Roche, Dr Serge Gauthier: Director of Alzheimer’s Disease Research Unit at McGill Centre for Studies in Ageing in Canada, Drug Trials Failure Rate, Epidemiology, Epidemiology and Statistics, Francesca Colombo: Organisation for Economic Co-operation and Development (OECD), Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Glenn Rees: Chairman of Alzheimer’s Disease International, Glenn Rees: Former CEO of Alzheimer’s Australia, Global Burden of Dementia, Global Dementia Discovery Fund (2015), Identification and Intervention for Dementia in Elderly Africans (IDEA Group), Jeff Cummings: Director of Cleveland Clinic at Lou Ruvo Centre for Brain Health, Kate Bingham: SV Health Managers, King’s College London, Market Failure (Dementia Research and Drug Development), Martin Knapp: London School of Economics, Memory Ageing and Cognition Centre at National University Health System: Singapore, Memory Ageing and Cognition Centre: National University Health System (Singapore), National Centre for Geriatrics and Gerontology (Japan), Optima (University of Oxford’s Dementia Research Project), OPTIMA Cohort (Oxford Project to Investigate Memory and Ageing), Oxford Project to Investigate Memory and Ageing (OPTIMA Study), Paola Barbarino: Alzheimer’s Disease International, Prevention, Prevention Agenda, Prevention of Future Dementia Cases by Increasing Knowledge of Risk and Protective Factors, Professor Adesola Ogunniyi: University College Hospital (Ibadan), Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Professor Craig Ritchie: Chair of Psychiatry of Ageing at University of Edinburgh, Professor Craig Ritchie: Director at Centre for Dementia Prevention, Professor Gordon Wilcock: Co-founder of Alzheimer’s Society UK, Professor Gordon Wilcock: Emeritus Professor of Geratology at University of Oxford, Professor Henry Brodaty: Director of Dementia Collaborative Research Centre at University of New South Wales, Professor Martin Knapp: Director of the Personal Social Services Research Unit at the London School of Economics and Political Science (LSE), Professor Martin Prince: Assistant Principal for Global Health at King’s College London, Research Networks, Ricardo Allegri: Head of Cognitive Neurology Neuropsychology and Neuropsychiatry at Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Risk and Protective Factors, State of the Art of Dementia Research: New Frontiers (World Alzheimer Report 2018), Supporting People Affected by Dementia, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Dementia Research Institute at UCL, University College Hospital (Ibadan Nigeria), World Alzheimer Report, World Alzheimer Report 2018: State of the Art of Dementia Research, World Alzheimer Report: 2018, World Alzheimer’s Day 2018 | Leave a comment

Young Blood Infusion Recapitulates Folklore: Vampire Therapy for Dementia? (Telegraph / CTAD / JPAD)

Posted on November 6, 2017 by Dementia and Elderly Care News

Summary A small trial to check the safety and tolerability of youthful blood infusions for the treatment or amelioration of Alzheimer’s Disease has detected early signs of improvement in activities of daily living. Randomly selected individuals from just 18 over-65 … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Non-Pharmacological Treatments, Quick Insights, Universal Interest | Tagged 10th Annual Clinical Trial on Alzheimer’s Disease (CTAD) Conference, Activities of Daily Living (ADLs), ADAS-Cog, Alkahest (San Carlos; USA), Alzheimer's Disease Assessment Scale (ADAS-Cog13), Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog), Alzheimer's Disease Co-operative Study - Activities of Daily Living Scale (ADCS-ADL), Alzheimer's Disease Co-operative Study-Activities of Daily Living Inventory (ADCS-ADL) Scale, Alzheimer’s Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), Alzheimer’s Disease Cooperative Study / Activities of Daily Living (ADCS-ADL) Inventory, Alzheimer’s Therapeutic Research Institute: University of Southern California, Assessments of Functional Ability, Clinical Dementia Rating Scale, Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), Department of Health Research and Policy: Stanford University, Department of Neurology and Neurological Sciences: Stanford University, Department of Neurosurgery: Stanford University, Department of Pediatrics: Stanford University, Disease Modification Trials, Disease Modifying Treatment by 2025 (Aim), Disease Modifying Versus Symptom Modifying Treatments (Widespread Mis-Classification in Drugs Development Pipeline), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Disease-Modifying Treatments for Dementia, Disease-Modifying Trials in Mild-to-Moderate Dementia, Folk Tales, Folklore, Functional Activities Questionnaire (FAQ), Geriatric Depression Scale, Geriatric Depression Scale (GDS Short Form), Infusion of Young Persons’ Plasma, Infusions of Plasma to Elderly People With Alzheimer’s Disease, Journal of Prevention of Alzheimer’s Disease (JPAD), Legends, Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory (NPI-Q), Outcome Measures for Disease-Modifying Trials in Mild-to-Moderate Dementia, PLASMA (Plasma for Alzheimer’s Symptom Amelioration) Trial, Plasma for Alzheimer’s Symptom Amelioration (PLASMA), Platelet-Rich Plasma Therapy (PRP), Repeated Infusions of Young Persons’ Plasma, Stanford University, The Journal of Prevention of Alzheimer's Disease, The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (PLASMA), Trail Making Test Part A (TMTA), Trail Making Test Part B (TMTB, United States, University of Southern California, USA, USA Endocrinology, Vampire Therapy, Vampirism, Young Plasma | Leave a comment

NICE Participation in European ROADMAP Project: Faster Access to Alzheimer’s Disease Drugs? (NICE)

Posted on January 12, 2017 by Dementia and Elderly Care News

Summary NICE is participating in the ROADMAP initiative, which is working on a sustainable platform for “real world” evidence generation concerning Alzheimer’s Disease and (hopefully) faster development of disease-modifying drugs. “The IMI (Innovative Medicines Initiative) is Europe’s largest public-private partnership, … Continue reading →

Posted in Commissioning, For Researchers (mostly), In the News, International, National, Quick Insights, UK, Universal Interest | Tagged Academia-Industry Partnerships, Big Data, Big Data for Better Outcomes Programme (IMI), Big Data Funding and Research, Collaborative Projects, Cross-Sector Partnerships, Data Sharing, Dementia Research, Disease Modification, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Treatments for Dementia, Dr Matthew Norton: Alzheimer's Research UK, Electronic Health Records (EHRs), European ROADMAP Project, Global Leadership, Global Outlook, IMI (Innovative Medicines Initiative), IMI’s Big Data for Better Outcomes Programme, Innovative Medicines Initiative (IMI), International Collaborations, International Programmes, Leveraging Big Data, National Institute for Health and Care Excellence (NICE), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NICE’s Science Policy and Research Programme, Pan-European Collaborations, Partnership, Partnership and Collaboration, Partnership Working, Prof Carole Longson: National Institute for Health and Care Excellence (NICE), Professor Carole Longson: Director of Centre for Health Technology Evaluation at NICE, Professor John Gallacher: University of Oxford, Promisary Science, Publicly-Funded UK Big Data Research, Research and Innovation, Resource and Incentives, ROADMAP Initiative | Leave a comment

Tag Archives: Disease-Modifying Treatments for Dementia

Young Blood Infusion Recapitulates Folklore: Vampire Therapy for Dementia? (Telegraph / CTAD / JPAD)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites